Acquired hypercoagulable state in renal transplant recipients

Thrombosis and Haemostasis

Volumn 91, Issue 4, 2004, Pages 646-654

  Kazory, Amir ^a   Ducloux, Didier ^a  

^a HÔPITAL SAINT JACQUES   (France)

Author keywords

Hypercoagulability; Renal transplantation; Thromboembolism; Thrombosis

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTITHROMBIN III; AZATHIOPRINE; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; CALCINEURIN INHIBITOR; CARDIOLIPIN ANTIBODY; CORTICOSTEROID; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; FOLIC ACID; GLUCOCORTICOID; HOMOCYSTEINE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 6; LUPUS ANTICOAGULANT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NITRIC OXIDE; OKT 3; PHOSPHOLIPID ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR; RAPAMYCIN; TACROLIMUS; THEOPHYLLINE; TISSUE PLASMINOGEN ACTIVATOR; UNINDEXED DRUG; VON WILLEBRAND FACTOR;

ARTERY THROMBOSIS; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CYTOMEGALOVIRUS INFECTION; DEEP VEIN THROMBOSIS; DRUG MECHANISM; ERYTHROCYTOSIS; HEMODIALYSIS; HEPATIC ARTERY; HUMAN; HYPERCOAGULABILITY; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL; PROTEINURIA; RECIPIENT; REVIEW; RISK FACTOR; THROMBOEMBOLISM;

EID: 1842637340     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/th03-09-0568     Document Type: Review

References (106)

1. Irish AB, Green FR. Environmental and genetic determinants of the hypercoagulable state and cardiovascular disease in renal transplant recipients. Nephrol Dial Transplant 1997; 12: 167-73.
2. Allen RD, Michie CA, Murie JA et al. Deep venous thrombosis after renal transplantation. Surg Gynecol Obstet 1987; 164: 137-42.
3. Humar A, Johnson EM, Gillingham KJ et al. Venous thromboembolic complications after kidney and kidney-pancreas transplantation. Transplantation 1998; 65 (2): 229-34.
4. Advisory committee to the renal transplant registry. The 12th report of the human renal transplant registry. JAMA 1975; 233: 787-93.
5. European and dialysis and transplant association. Combined report on regular dialysis and transplantation in Europe. London: Pitman, 1983: 13.
6. Vanrenterghem Y, Roels L, Lerut T et al. Thromboembolic complications and haemostatic changes in cyclosporin-treated cadaveric kidney allograft recipients. Lancet 1985; 1 (8436): 999-1002.
7. Carlsen E, Prydz H. Enhancement of procoagulant activity in stimulated mononuclear blood cells and monocytes by cyclosporine. Transplantation 1987; 43 (4): 543-8.
8. Fishman SJ, B.S. W, Glickman JD et al. Cyclosporin A augments human platelet sensitivity to aggregating agents by increasing fibrinogen receptor availability. J Surg Res 1991; 51: 93-8.
9. Bombeli T, Muller M, Werner Straub P et al. Cyclosporine-induced detachment of vascular endothelial cells initiates the extrinsic coagulation system in plasma and whole blood. J lab Clin Med 1996; 127: 621-34.
10. Levi M, Wilmink J, Buller HR. Impaired fibrinolysis in cyclosporine-treated renal transplant patients. Transplantation 1992; 54(6): 978-83.
11. Garcia-Maldonaldo M, Kaufman CE, Comp PC. Decrease in endothelial cell-dependent protein C activation induced by thrombomodulin by treatment by cyclosporine. Transplantation 1991; 51 (3): 701-5.
12. Petric R, Freeman D, Wallace C et al. Effect of cyclosporine on urinary prostinoid excretion, renal blood flow and glomerotubular function. Transplantation 1998; 45: 883-9.
13. Brown Z, Neild GH. Cyclosporine inhibits prostacyclin production by cultured human endothelial cells. Transplant Proc 1987; 19: 1178-80.
14. Hornung N, Degiannis D. Up-regulation by cyclosporine(CsA) of the in vitro release of soluble CD23 and of the in vitro production of IL-6 and IgM. Scand J Immunol 1993; 38 (3): 287-92.
15. Dalmon J, Laurent M, Courtois G. The human beta fibrinogen promoter contains a hepatocyte nuclear factor 1-dependent interleukin-6-responsive element. Mol Cell Biol 1993; 13(2): 1183-93.
16. Malyszko J, Malyszko JS, Pawlak K et al. The coagulo-lytic system and endothelial function in cyclosporine-treated kidney allograft recipients. Transplantation 1996; 62 (6): 828-30.
17. van der Dropel MA, Man in't Veld AJ, Levi M et al. Beneficail effects of conversion from cyclosporine to azathioprine on fibrinolysis in renal transplant recipients. Arterioscler Thromb Vasc Biol 1999; 19: 1555-8.
18. Huser B, Lammle B, Landmann J et al. Von Willebrand factor and factor VIII in renal transplant recipients under immunosuppression with cyclosporine and steroids. Se-quential measurements over 4 months in 17 patients. Clin Nephrol 1990; 34 (5): 214-22.
19. Brunkwall J, Bergqvist D, Bergentz SE et al. Postoperative deep vein thrombosis after renal transplantation. Transplantation 1987; 43(5): 647-9.
20. Gruber SA, Pescovitz MD, Simmons RL et al. Thromboembolic complications in renal allograft recipients. Transplantation 1987; 44: 775-8.
21. Penny MJ, Nankivell BJ, Disney APS et al. Renal graft thrombosis. Transplantation 1994; 58 (5): 565-9.
22. Gruber SA, Chavers B, Payne et al. allograft renal vascular thrombosis-lack of increase with cyclosporine immunosuppression. Transplantation 1989; 47 (3): 475-8.
23. Irish A. Renal allograft thrombosis: Can thrombophilia explain the inexplicable? Nephrol Dial Transplant 1999; 14: 2297-303.
24. Muraki T, Sasaki Y, Giddings JC et al. Antithrombotic effect of FK506 versus prothrombotic effect of cyclosporine in vivo. Transplantation 1995; 60: 308-10.
25. Muraki T, Taka T, Noguchi T et al. Effects of cyclosporine and FK506 on in vitro high shear-induced platelet reactivity in rat and human non-anticoagulated blood. Transplantation 1998; 65: 1132-4.
26. Freudenbereger R, Alexis J, Gass A et al. Antithrombotic effect of FK506 vs cyclosporine in cardiac transplant recipients: potential implications in transplant arteriopathy. J Heart Lung Transplant 1999; 18: 1228-31.
27. Pirsch JD, Miller J, Deierhoi MH et al. A comparison of Tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997; 63: 977-83.
28. Ozsoylu S, Strauss HS, Diamond LK. Effects of corticosteroids on coagulation of the blood. Nature 1962; 195: 1214-8.
29. Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol 1990; 6: 217-20.
30. Laung WE. Glucocorticoids inhibit plasminogen activator production by endothelial cells. Thromb Haemost 1983; 50: 888-91.
31. Patrassi GM, Sartori MT, Rigotti P et al. Coagulation and fibrinolysis during the first year of immunosuppressive treatment in renal transplantation : Correspondence between hypercoagulable state and steroid therapy. Clin Appl Thrombosis Hemosta 1995; 1: 277-81.
32. Patrassi GM, Sartori MT, Rigotti P et al. Reduced fibrinolytic potential one year after kidney transplantation : relationship to long-term steroid treatment. Transplantation 1995; 59: 1416-9.
33. Sartori MT, Patrassi GM, Rigotti P et al. Improved fibrinolytic capacity after withdrawal of steroid immunosuppression in renal transplant recipients. Transplantation 2000; 69 (10): 2116-21.
34. Sartori MT, Rigotti P, Marchini F et al. Plasma fibrinolytic capacity in renal transplant recipients : Effect of steroid-free immunosuppression therapy. Transplantation 2003; 75 (7): 994-8.
35. Salmeron A, Sanchez Madrid F, Ursa RM et al. A conformational epitope expressed upon association of CD-3 epsilon with either CD-3 delta or CD-3 gamma is the main target for recognition by anti-CD3 monoclonal antibodies. J immunol 1991; 147: 3047-52.
36. Pradier O, Marchant A, Abramowicz D et al. Procoagulant effect of the OKT3 monoclonal antibody: Involvement of tumor necrosis factor. Kidney Int 1992; 42: 1124-9.
37. Lozano M, Oppenheimer F, Cofan F et al. Platelet procoagulant activity induced in vivo by munomorab-CD3 infusion in uremic patients. Thromb Res 2001; 104: 405-11.
38. Abramowicz D, Pradier O, Marchant A et al. Induction of thromboses within renal grafts by high-dose prophylactic OKT3. Lancet 1992; 339: 777-8.
39. Abramowicz D, Pradier O, De Pauw L et al. High-dose glucocorticoids increase the procoagulant effects of OKT3. Kidney 1994; 46 (6): 1596-602.
40. Shankar R, Bastani B, Salinas-Madrigal L et al. Acute thrombosis of the renal transplant artery after a single dose of OKT3. Am J Nephrol 2001; 21 (2): 141-4.
41. Babinska A, Markell MS, Salifu MO et al. Enhancement of human platelet aggregation and secretion induced by rapamycin. Nephrol Dial Transplant 1998; 13: 3153-9.
42. Data on file. Wyeth Ayerst Pharmaceuticals 2002.
43. Dunkelberg JC, Trotter JF, Wachs M et al. Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications. Liver Transplant 2003; 9 (5): 463-8.
44. MacDonald AS, for the Rapamune® Global Study Group. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71: 271-80.
45. Langer RM, Kahan BD. Sirolimus does not increase the risk for postoperative thromboembolic events among renal transplant recipients. Transplantation 2003; 76 (2): 318-23.
46. Klein BC, Bach D, Rehfeld I et al. Influence of Mycophenolic Acid and FK-506 on human platelet activation in vitro. Kidney Blood Press Res 2000; 23: 119-24.
47. Malyszko J, Malyszko JS, Mysliwiec. Effects of Mycophenolate Mofetil and Mycophenolic Acid on platelet aggregation in vitro. Transplant Proc 2000; 32: 1347-9.
48. Cherney DZI, Zaltzman JS. Mycophenolate mofetil causing deep venous thrombosis in a renal transplant patient with factor V Leiden. Nephrol Dial Transplant 2001; 16: 1702-4.
49. Harris EN, Gharari AE, Boey ML. Anti-cardiolipin antibodies: detection by radioimmunoassay and association with thrombosis. Lancet 1983; 2: 12112-4.
50. Rysava R, Zabka J, Peregrin JH et al. Acute renal failure due to bilateral renal artery thrombosis associated with primary antiphspholipid syndrome. Nephrol Dial Transplant 1998; 13: 2645-7.
51. Harris EN, Asherson RA, Hugues GR. Antiphospholipid antibodies: Autoantibodies with a difference. Annu Rev Med 1988; 39: 261-4.
52. Khamashta MA, Harris EN, Gharavi AE et al. Immune mediated mechanism for thrombosis: Antiphospholipid antibody binding to platelet membranes. Ann Rheum Dis 1988; 47: 849-52.
53. Carreras LO, Defreyn G, Machin SJ et al. Arterial thrombosis, intrauterine death and the lupus anticoagulant: Detection of immunoglobulin interfering with prostacyclin formation. Lancet 1981; 1: 244-6.
54. Ruiz-Arguelles GJ, Ruiz-Arguelles A, Deleze M et al. Acquired protein C deficiency in a patient with ptimary phospholipid syndrome: relationship to reactivity of anticardioplipin antibody with thrombomodulin. J Rheumatol 1989; 16: 381-4.
55. Ducloux D, Bourrinet E, Motte G et al. Antiphospholipid antibodies as a risk factor for atherosclerotic events in renal transplant recipients. Kidney Int 2003; 64: 1065-70.
56. Ducloux D, Pellet E, Fournier V et al. Prevalence and clinical significance of antiphospholipid antibodies in renal transplant recipients. Transplantation 1999; 67 (1): 90-3.
57. Knight RJ, Schanzer H, Rand JH et al. Renal allograft thrombosis associated with the antiphospholipid antibody syndrome. Transplantation 1995; 60 (6): 614-5.
58. Mondragon-Rameriz G, Bochicchio T, Garcia-Torres R et al. Recurrent renal thrombotic angiopathy after kidney transplantation in two patients with primary antiphospholipid syndrome. Clin Transplant 1994; 8: 93-6.
59. Wagenknecht DR, Becker DG, LeFor WM et al. Antiphospholipid antibodies are a risk factor for early renal allograft failure. Transplantation 1999; 68 (2): 241-6.
60. Nygard O, Nordrehaug NE, Refsum H et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337 (4): 230-6.
61. Boushey CJ, Beresfor SSA, GS O et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-57.
62. den Heijer M, Koster T, Blom HJ et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Eng J Med 1996; 334: 759-62.
63. Ducloux D, Motte G, Chalopin JM. Homocysteine in renal disease. Clin Lab 2000, 46: 141-51.
64. Bostom AG, Gohh RY, Tsai MY et al. Excess prevalence of fasting and PML hyper-homocysteinemia in stable renal transplant recipients. Arterioscler Thromb Vasc Biol 1997; 17: 1894-900.
65. Ducloux D, Motte G, Challier B et al. Serum total homocysteine and cardiovascular disease occurrence in chronic stable renal transplant recipients: A prospective study. J Am Soc Nephrol 2000, 11: 134-7.
66. Ducloux D, Ruedin C, Gibey R et al. Prevalence, determinants, and clinical significance of hyperhomocysteinemia in renal transplant recipients. Nephrol Dial Transplant 1998; 13: 2890-3.
67. Arnadottir M, Hultberg B, Vladov V et al. Hyperhomocysteinemia in cyclosporine-treated renal transplant recipients. Transplantation 1996; 61: 509-12.
68. Cole DE, Ross HJ, Evrovski J et al. Correlation between total homocysteine and cyclosporine concentrations in cardiac transplant recipients. Clin Chem 1998; 44 (11): 2307-12.
69. Bostom AG, Gohh RY, Beaulieu AJ et al. Determinants of fasting total homocysteine levels among chronic stable renal transplant recipients. Transplantation 1999; 68 (2): 257-61.
70. Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb Haemost 1999; 81: 165-76.
71. Cattaneo M, Tsai MY, Bucciarelli P et al. A common methylenetetrahydrofolate reductase gene (C667T) increase the risk for deep-vein thrombosis in patients with mutant factor V (factor V: Q506). Arterioscler Thromb Vasc Biol 1997; 17: 1662-6.
72. Abdelfatah A, Ducloux D, Toubin G et al. Treatment of hyperhomocysteinemia with folic acid reduces oxidative stress in renal transplant recipients. Transplantation 2002; 73 (4): 663-5.
73. Marcucci R, Brunelli T, Giusti B et al. The role of cysteine and homocysteine in venous and arterial thrombotic disease. Am J Clin Pathol 2001; 116 (1): 56-60.
74. Marcucci R, Fedi S, Brunelli T et al. High cysteine levels in renal transplant recipients : Relationship with hyperhomocysteinemia and 5,10-MTHFR polymorphism. Transplantation 2001; 71 (6): 746-51.
75. Thervet E, Anglicheau D, Legendre C. Recent issues concerning renal transplantation in systemic lupus erythematosus patients. Nephrol Dial Transplant 2001; 16: 12-4.
76. Stone JH, Amend WJ, Criswell LA. Antiphospholipid antibody syndrome in renal transplantation: Occurrence of clinical events in 96 consecutive patients with systemic lupus erythematosus. Am J Kidney Dis 1999; 34 (6): 1040-7.
77. Radhakrishnan J, Williams GS, Appel GB et al. Renal transplantation in anticardiolipin antibody-positive lupus erythematosus patients. Am J Kidney Dis 1994; 23 (2): 286-9.
78. Karassa FB, Konstandina A, Pappas P et al. Late renal transplant thrombosis in a patient with systemic lupus erythematosus and antiphospholipid syndrome. Nephrol Dial Transplant 1999; 14: 472-4.
79. Friedman GS, Wik D, Silva L et al. Allograft loss in renal transplant recipients with Fabry's disease and activated protein C resistance. Transplantation 2000; 69 (10): 2099-2102.
80. Chang HS, Ro LS, Chen ST. Fabry's disease: Report of a case. J Formosan Medical Association 1995; 94 (6): 346-50.
81. Hirshfield G, Collier JD, Brown K et al. Donor factor V Leiden mutation and vascular thrombosis following liver transplantation. Liver Transplant Surg 1998; 4 (1): 58-9.
82. Kanfer A. Thromboses and Hemostasis disorders in nephrotic syndrome. Nophrologie 1992; 13: 347-59.
83. Mannucci PM, Valsecchi C, Bottasso B et al. High plasma levels of protein C activity and antigen in the nephrotic syndrome. Thromb Haemost 1986; 55: 31-3.
84. Sagripanti A, Barsotti G. Hypercoagulability, intraglomerular coagulation, and thromboembolism in nephrotic syndrome. Nephron 1995; 70; 271-81.
85. Colle JP, Mishal Z, Lesty C et al. Abnormal fibrin clot architecture in nephrotic patients is related to hypofibrinolysis: influence of plasma biochemical modifications: A possible mechanism for the high thrombotic tendency? Thromb Haemost 1999; 82: 1482-9.
86. Biesenbach G, Janko O, Hubmann R et al. The incidence of thrombovenous and thromboembolic complications in kidney transplant patients with recurrent glomerulonephritis is dependent on the occurrence of severe proteinuria. Clin Nephrol 2000; 54 (5): 382-7.
87. Bertoli M, Gasparotto, ML, Vertolli U et al. Does hypercoagulability exist in CAPD patients? Perit Dial Bull 1984; 4: 237-9.
88. Kobayashi M, Yorioka N, Yamakido M. Hypercoagulability and secondary hyperfibrinolysis may be related to abnormal lipid metabolism in patients treated with continuous ambulatory peritoneal dialysis. Nephron 1997; 76: 56-61.
89. Van Der Vliet JA, Barendregt WB, Hoitsma AJ et al. Increased incidence of renal allograft thrombosis after continuous ambulatory peritoneal dialysis. Clin Transplant 1996; 10: 51-4.
90. Ojo AO, Hanson JA, Wolfe RA et al. Dialysis modality and and the risk of allograft thrombosis in adult renal transplant recipients. Kidney Int 1999; 55: 1952-60.
91. Snyder JJ, Kasiske BL, Gilbertson DT et al. A comparison of transplant outcomes in peritoneal and hemodialysis patients. Kidney Int 2002; 62: 1423-30.
92. Sumrani NB, Daskalakis P, Miles AM et al. Erythrocytosis after renal transplantation: A prospective analysis. ASAIO J 1993; 39: 51-5.
93. Qunibi WY, Barri Y, Devol A et al. Factors predictive of post-transplant erythrocytosis. Kidney Int 1991; 40: 1153-9.
94. Kahan BD, Ponticelli C, Aroldi A et al. Musculoskeletal, ocular and hematological complications. In: Kahan BD, Ponticelli C, eds. Principles and practice of renal transplantation. Martin Dunitz, London, 2000; 693-719.
95. Wickre CG, Norman DJ, Bennison A et al. Postrenal transplant erythrocytosis : A review of 53 patients. Kidney Int 1983; 23: 731-7.
96. Hestin D, Legrand E, Mertes M et al. Polycythemia after kidney transplantation. Presse Med 1992; 21 (41): 1973-4.
97. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.9.3 Haematological complications. Erythrocytosis. Nephrol Dial Transpl 2002; 17 suppl 4: 49-50.
98. Montanaro D, Groupuzzo M, Boscutti G et al. Long-term therapy for postrenal transplant erythrocytosis with ACE inhibitors: Efficacy, safety, and action mechanisms. Clin Nephrol 2000; 53 (4) suppl 47-51.
99. Julian BA, Brantley RRJ, Barker CV et al. Losartan, an angiotensin II type 1 receptor antagonist lowers hematocrit in post-transplant erythrocytosis. J Am Soc Nephrol 1998; 9: 1104-8.
100. Bakris GL, Sauter ER, Hussey JL et al. Effects of theophylline on erythropoietin production in normal subjects and in patients with erythrocytosis after renal transplantation. N Eng J Med 1990; 323: 86-90.
101. Bruggeman CA, Debie WN, Muller AD et al. Cytomegalovirus alters von Willebrand factor content in human endothelial cells. Thromb Haemost 1988; 59: 264-70.
102. Van Dam-Mieras MCE, Muller AD, Van Hinsbergh VWM et al. The procoagulant response of cytomegalovirus infected endothelial cells. Thromb Haemost 1992; 68; 364.
103. Toyoda M, Galfayan K, Galera OA et el. CMV infection induces anti-endothelial cell antibodies in cardiac and renal graft recipients. Transplant Immun 1997; 5: 104-11.
104. Neumann FJ, Kastrati A, Miethke T et al. Previous cytomegalovirus infection and risk of coronary thrombotic events after stent placement. Circulation 2000; 101: 11-3.
105. Abgueguen P, Delbos V, Chennebault JM et al. Vascular thrombosis and acute cytomegalovirus infection in immunocompetent patients: Report of 2 cases and literature review. Clin Infect Dis 2003; 36: 134-9.
106. Muldoon J, O'Riordan K, Rao S et al. Ischemic colitis secondary to venous thrombosis. Transplantation 1996; 61(11): 1651-3.